 | |
| Type | biotechnology/pharmaceutical |
|---|---|
| Founded | 1994 in Seattle, Washington |
| Defunct | March 31, 2006 |
| Successor | acquired by GlaxoSmithKline |
| Headquarters | Seattle , Washington |
Number of locations | 2 |
| Parent | GlaxoSmithKline (United States)  |
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.
On 12 July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
On 31 March 2006, Corixa's doors closed after over 11 years in business.
External links
- "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.
References
- ↑ "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.